2020
Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis
Bewersdorf JP, Giri S, Wang R, Podoltsev N, Williams RT, Rampal RK, Tallman MS, Zeidan AM, Stahl M. Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis. Clinical Lymphoma Myeloma & Leukemia 2020, 20: e712-e723. PMID: 32669244, PMCID: PMC7541411, DOI: 10.1016/j.clml.2020.05.018.Peer-Reviewed Original ResearchConceptsOverall response rateTreatment of myelofibrosisPEG-IFNMF patientsResponse rateHematologic responseSystematic reviewFormulations of interferonPartial hematologic responseCochrane Central RegisterComplete hematologic responseRisk of progressionRole of interferonAcute myeloid leukemiaPhiladelphia chromosome-negative myeloproliferative neoplasmsRandom-effects modelBone marrow failureWeb of ScienceTreatment discontinuationCentral RegisterConstitutional symptomsHematologic improvementInterferon therapyAdverse eventsComplete response
2003
Interferon-Induced Sarcoidosis
Rubinowitz AN, Naidich DP, Alinsonorin C. Interferon-Induced Sarcoidosis. Journal Of Computer Assisted Tomography 2003, 27: 279-283. PMID: 12703026, DOI: 10.1097/00004728-200303000-00030.Peer-Reviewed Original ResearchConceptsHepatitis C virus infectionNonspecific constitutional symptomsC virus infectionHepatitis C infectionCases of sarcoidosisC infectionConstitutional symptomsInterferon therapyPulmonary involvementImportant complicationNonmalignant diseasesVirus infectionInvasive proceduresSide effectsTherapySarcoidosisPatientsInfectionComplicationsInterferonSymptomsDiseasePhysiciansUncommon
1984
Urinary excretion of interferon, albumin, and beta 2-microglobulin during interferon treatment.
Sumpio BE, Ernstoff MS, Kirkwood JM. Urinary excretion of interferon, albumin, and beta 2-microglobulin during interferon treatment. Cancer Research 1984, 44: 3599-603. PMID: 6378373.Peer-Reviewed Original ResearchConceptsInterferon therapyUrinary excretionInterferon activityPhase I trialSerum interferon activityUrinary betaInterferon administrationI trialSignificant nephrotoxicityTubular lesionsUrinary levelsInterferon treatmentHighest dosing levelDosing levelsTherapyInterferonExcretionTreatmentLow affinityAlbuminBetaNephrotoxicityPatientsLesionsPharmacokinetics
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply